Inhibitex, Inc. (NASDAQ: INHX), a biopharmaceutical company focused on the development of products to treat serious infectious diseases, announced today that it has completed a Phase I single ascending dose (SAD) clinical trial and initiated a multiple ascending dose (MAD) trial of FV-100, a highly potent and fast-acting compound being developed to treat shingles (herpes zoster).

More: continued here

This entry was posted on Monday, August 11th, 2008 at 9:08 am and is filed under Clinical Trials. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.